Maxim Group analyst Anthony Vendetti reiterated a Buy rating on NeuroOne Medical Technologies yesterday and set a price target of $3.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Anthony Vendetti has given his Buy rating due to a combination of factors including NeuroOne Medical Technologies’ impressive preliminary revenue results for FY25, which exceeded both consensus and internal estimates. The growth is attributed to the strategic partnership with Zimmer Biomet, which has enhanced the company’s sales capabilities and contributed to increased procedure volumes.
Additionally, the company’s efforts in building awareness through partnerships with patient advocacy groups and media exposure have bolstered interest in its innovative treatments. NeuroOne’s advancement in its broader platform, including new applications for facial pain and spinal cord stimulation, further demonstrates its potential in addressing large market opportunities. The company’s strong financial position, with sufficient capital to operate into FY27, and its compelling valuation, support the reiterated Buy rating.
NMTC’s price has also changed dramatically for the past six months – from $0.433 to $1.060, which is a 144.80% increase.